ClinicalTrials.gg
Enrolling by invitationNCT07601295ATHENAUpdated Nov 19, 2026

Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

A Phase 2 interventional study of Tiprelestat (5 mg) and Placebo (1 mL 0.9% saline solution) in Pulmonary Arterial Hypertension (PAH), sponsored by Marlene Rabinovitch, MD. Enrolling by invitation at 10 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Marlene Rabinovitch, MD · Phase 2, Interventional, and Treatment

How we know

Updated Nov 19, 2026Now Enrolling by invitationStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 313 studies in Pulmonary Arterial Hypertension with a site in United States — 38 open to participants now, 56 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.

Planned enrollment
74th of 253
90 · median 40
Started
2026
with 12 others
Phase 2
82 of 313
11 open now
Primary completion
2030-02
later than 49 of 55 live
Registered
307th of 313
by date

Among the 313 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 74th largest by planned enrollment of the 253 interventional ones that give a count, is one of 13 that started in 2026, is one of 82 in phase 2, reaches primary completion later than 49 of the 55 other live ones, and was the 307th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

38 of the 313 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 313 studies in Pulmonary Arterial Hypertension with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to compare the efficacy, safety, and tolerability of tiprelestat plus Standard of Care (SOC) compared with placebo plus SOC in patients with World Health Organization (WHO) functional class II-IV pulmonary arterial hypertension (PAH).

03

Conditions studied

  • Pulmonary Arterial Hypertension (PAH)

Keywords

  • tiprelestat
  • elafin
  • pulmonary arterial hypertension
  • PAH
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults age 18 to 75 years.
  2. Willingness to give written prior to any study-related procedures being performed and to be able to adhere to the study restrictions and examination schedule.
  3. Diagnosis of WHO Group I PAH.
  4. WHO functional class II - IV despite optimized treatment SOC, with 1 or more modalities including phosphodiesterase 5 (PDE5) inhibitor, soluble guanylate cyclase stimulator (sGCS), endothelin receptor antagonist (ERA), and/or a prostacyclin analogue or receptor agonist (SC/inhaled/PO) (see #5), as well as Sotatercept (see #6).
  5. On stable doses of PDE5 inhibitor, ERA, sGCS, or prostacyclin analogue/receptor agonist for at least 90 days prior to screening; for infusion prostacyclins, dose adjustment within 10% of baseline dose during the duration of the study is allowed per medical practice.
  6. On stable doses of Sotatercept therapy for at least 6 months prior to screening, and intended to be continued during the duration of the study.
  7. Screening right heart catheterization mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg at rest; pulmonary wedge pressure (PAWP) ≤ 15 mmHg or left ventricular end diastolic pressure (LVEDP) ≤ 15 mmHg; AND pulmonary vascular resistance (PVR) ≥ 400 dynes•sec/cm5 (5 Wood Units).
  8. If participant is of , willing to use adequate methods of throughout the course of the study. If participant is of childbearing potential (a participant \< 55 years of age who has not been for ≥ 5 years or who has not had a bilateral salpingectomy, hysterectomy and/or oophorectomy), need to employ two reliable means of contraception which may include surgical sterilization, barrier methods, spermicidals, intrauterine devices, and/or hormonal contraception, unless the participant chooses abstinence (to avoid heterosexual intercourse completely). If a participant chooses abstinence, then a second reliable means of contraception is not needed.
  9. 6MWD ≥100 and ≤500 meters at screening.
  10. Willing to adhere to study restrictions and examination schedule.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of WHO Group 2 - 5 Pulmonary Hypertension.
  2. Participation in another clinical trial, or experimental use, involving a PAH drug or device within the last 3 months.
  3. Total lung capacity (TLC) \< 60% predicted; if TLC is ≥ 60% and \< 70% predicted, high resolution computed tomography (HRCT) must be available to exclude significant interstitial lung disease.
  4. / FVC \< 70% predicted and FEV1 \< 60% predicted.
  5. Significant left-sided heart disease (based on screening Echocardiogram):

    1. Moderate or severe aortic or mitral valve disease
    2. Diastolic dysfunction ≥ Grade II
    3. LV systolic function \< 45%
    4. Pericardial constriction
    5. Restrictive cardiomyopathy
    6. Significant coronary disease with demonstrable ischemia
  6. Chronic renal insufficiency defined as an estimated \< 30 ml/min.
  7. Current atrial arrhythmias not under optimal control.
  8. Uncontrolled systemic hypertension: SBP > 160 mmHg or DBP > 100mmHg.
  9. Severe hypotension: SBP \< 80 mmHg.
  10. Pregnant or breast-feeding.
  11. Psychiatric, addictive, or other disorders that compromise the patient's ability to provide , to follow study protocol, and adhere to treatment instructions.
  12. Known allergy or to tiprelestat.
  13. Moderate to severe hepatic dysfunction with a score >10.
  14. Hyperkalemia defined as Potassium > 5.1 mEq/L at screening.
  15. Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days prior to screening or planned during the study. Subjects who are already stable in the maintenance phase of an exercise program which will continue for the duration of the study are eligible.
  16. Known active infection requiring antibiotic, antifungal, or antiviral therapies. Patients may be rescreened at physician discretion after the resolution of infection and discontinuation of antibiotic, antifungal, or antiviral therapies.
  17. Co-morbid conditions that would impair a patient's exercise performance and ability to assess WHO functional class, including but not limited to chronic low-back pain or peripheral musculoskeletal problems, other comorbidities expected to alter the patient's clinical course (i.e. active cancer; >3 comorbidities e.g., obesity, systemic HTN, diabetes).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Tiprelestat (5 mg)

    Participants receive tiprelestat injection daily for 168 days.

    Drug: Tiprelestat (5 mg)

  • Experimental
    Tiprelestat (10 mg)

    Participants receive tiprelestat injection daily for 168 days.

    Drug: Tiprelestat (10 mg)

  • Placebo comparator
    Placebo (1 mL 0.9% saline solution)

    Participants receive placebo injection (matching tiprelestat) daily for 168 days.

    Drug: Placebo (1 mL 0.9% saline solution)

Interventions

  • DrugTiprelestat (5 mg)

    5 mg of tiprelestat in 1 mL saline administered as a daily subcutaneous injection for 168 days.

    Also known as: Elafin

  • DrugPlacebo (1 mL 0.9% saline solution)

    Matching 1 mL 0.9% saline solution administered as a daily subcutaneous injection for 168 days.

  • DrugTiprelestat (10 mg)

    10 mg of tiprelestat in 1 mL saline administered as a daily subcutaneous injection for 168 days.

    Also known as: Elafin

06

What researchers measure

Primary outcomes

  1. Change in Pulmonary Vascular Resistance (PVR)

    PVR is calculated based on direct measurements during the right heart catheterization (RHC) procedure. PVR = (mPAP - PAWP) / CO, where mPAP is the mean pulmonary artery pressure, PAWP is the pulmonary wedge arterial pressure, and CO is the cardiac output. These cardiac measures are also obtained from right heart catheterization. PVR is measured in Wood units (WU) or dynes (dynes\*sec/cm5), and higher values are associated with more severe disease. Normal range for PVR is 1-3 WU (80-240 dynes\*sec/cm5) and can be as high as 30 WU (2,400 80-240 dynes\*sec/cm5) in disease.

    Time frame: Baseline to week 24

07

Study locations

10 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Feb 2030, 39 months after the start.

Of 52 phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's planned 39 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Nov 2026, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
May 22, 2026
StartActual
Nov 4, 2026was Jul 2026
Primary completionEst.
Feb 2030
CompletionEst.
Mar 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Nov 19, 2026
Start date
Jul 2026→Nov 4, 2026 (actual)
Nov 19, 2026
Sponsor
Stanford University→Marlene Rabinovitch, MD
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Enrolling by invitation
    Start date Jul 2026→Nov 4, 2026 (now actual)
    Sponsor Stanford University→Marlene Rabinovitch, MD
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07601295
Lead sponsor
Marlene Rabinovitch, MD
Responsible party
Roham T. Zamanian (The James & Yvonne Wood Professor of Pulmonary Vascular Medicine; Director, Adult Pulmonary Hypertension Program; Associate Director, Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford University) — Principal investigator
First posted
May 22, 2026
Start date
Nov 4, 2026
Primary completion
Feb 2030 (estimated)
Completion
Mar 2030 (estimated)
Last update
Nov 19, 2026

Study contacts

Roham T Zamanian, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion